MT
Merlin Therapeutics develops therapeutic candidates aimed at treating neurofibromatosis type 2 (NF2), a rare genetic disorder that causes benign tumors on the auditory nerves. The company focuses on drug discovery and clinical development to address the underlying Merlin protein deficiency, targeting patients with limited treatment options. Revenue is generated through partnerships, licensing agreements, and eventual product sales upon regulatory approval.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Merlin Therapeutics focuses on developing therapies to treat neurofibromatosis type 2 (NF2), a genetic disorder that causes tumors on the auditory nerves. The company conducts preclinical and clinical research to identify and advance drug candidates targeting the underlying genetic defects of NF2. Its goal is to provide patients with effective treatment options that address tumor growth and associated hearing loss.